Ala. High Court To Reconsider Landmark Generic-Drug Ruling
By Greg Ryan (June 14, 2013, 6:37 PM EDT) -- The Alabama Supreme Court agreed Thursday to reconsider its January ruling that makers of brand-name drugs can be held liable for injuries caused by their generic counterparts, after Pfizer Inc. and another company called the decision an "extreme outlier position."
The high court issued an order saying it would hold oral argument in the case in September. Pfizer, its subsidiary Wyeth Ltd. and Schwarz Pharma Inc. requested oral argument in a brief in February, arguing that the court had misunderstood the U.S. Supreme Court's Mensing decision. According to Pfizer, the court did not hold oral argument before issuing the ruling.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!